Skip to main content
LYEL logo

LYEL

Lyell Immunopharma, Inc.
$14.04 -0.01 (-0.07%) At close · Jul 6
Market Cap
$327.61M
Shares
23,334,087

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025
Executive Total
Lynn Seely $4,222,265
Stephen Hill $2,076,439
Gary Lee $1,942,621
Fiscal 2024
Executive Total
Matthew Lang $1,869,632
Lynn Seely $1,495,376
Stephen Hill $1,342,842
Gary Lee $1,309,478
Fiscal 2023
Executive Total
Charles Newton $4,317,424
Matthew Lang $4,008,353
Stephen Hill $3,108,128
Lynn Seely $2,647,476
Tina Albertson $2,391,403
Gary Lee $2,226,356
Fiscal 2022
Executive Total
Lynn Seely $18,686,189
Elizabeth Homans $12,119,604
Gary Lee $4,128,472
Stephen Hill $4,068,026
Rahsaan W. Thompson $3,924,659
Charles Newton $3,875,468
Matthew Lang
Tina Albertson
Fiscal 2021
Executive Total
Richard Klausner $33,366,629
Charles Newton $20,124,792
Elizabeth Homans $18,643,569
Stephen Hill $2,251,930
Matthew Lang
Rahsaan W. Thompson
Lynn Seely
Tina Albertson
Gary Lee
Fiscal 2020
Executive Total
Richard Klausner $38,852,236
Elizabeth Homans $18,869,275
Stephen Hill $2,861,732
Lynn Seely
Rahsaan W. Thompson
Gary Lee
Charles Newton
Key facts CIK 1806952 CUSIP 55083R203 13F (30d) 1 filings 1 filers Visit website Investor relations